RNA Therapeutics Market Size & Growth Forecast 2027–2036, By Segments (Product, Indication, Type, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

RNA Therapeutics Market size was assessed at USD 22.13 Billion in 2026 and is poised to grow at 6.04% CAGR between 2027 and 2036, exceeding USD 39.78 Billion by 2036. The industry revenue for 2027 is calculated at USD 23.27 Billion.

• Base Year Value (2026): USD 22.13 Billion
• CAGR (2027-2036): 6.04%
• Forecast Year Value (2036): USD 39.78 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

RNA Therapeutics Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held 38.88% in 2025, supported by strong biotechnology research, advanced healthcare infrastructure, clinical capabilities, and investment in novel therapeutic development.
  • Asia Pacific is anticipated to grow fastest as biotechnology capabilities, healthcare investment, clinical research infrastructure, and domestic biopharmaceutical ecosystems expand.

• Segment Momentum:

  • Vaccines accounted for 68.83% of the market in 2025 and remained the fastest-growing product segment due to rapid development, adaptability, and continued advances in RNA delivery technologies and manufacturing capabilities.
  • RNAi therapeutics are gaining momentum as research increasingly targets gene-silencing therapies for genetic and chronic disorders, supported by advances in delivery technologies and growing interest in precision medicine.

• Market Expansion Drivers:

  • Advancements in RNA delivery technologies improving therapeutic effectiveness and safety
  • Rising incidence of infectious diseases increasing demand for RNA-based treatments
  • Expanding precision medicine initiatives accelerating RNA therapeutic development pipelines

• Leading Market Participants:

  Key players in the RNA therapeutics market include Moderna, Inc. (United States), BioNTech SE (Germany), Alnylam Pharmaceuticals, Inc. (United States), Ionis Pharmaceuticals, Inc. (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Sanofi S.A. (France), Sarepta Therapeutics, Inc. (United States), Arrowhead Pharmaceuticals, Inc. (United States), Regeneron Pharmaceuticals, Inc. (United States)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 22.13 Billion
  • 2027 Estimated Market Size: USD 23.27 Billion
  • Projected Market Size: USD 39.78 Billion by 2036
  • Growth Forecasts: 6.04% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Vaccines (Product) | Infectious Diseases (Indication) | mRNA Therapeutics (Type) | Hospitals (End-use)
  • Emerging Opportunity Segment: Vaccines (Product) | Infectious Diseases (Indication) | RNA Interference (RNAi) Therapeutics (Type) | Academic & Research Institutes (End-use)

Market Growth Drivers and Industry Trends

Advancements in RNA delivery technologies improving therapeutic effectiveness and safety

Continuous innovation in targeted delivery platforms will drive the RNA therapeutics market growth by improving the stability, precision, and safety of RNA-based treatments. Advanced delivery technologies are helping therapeutic molecules reach intended cells and tissues more efficiently while minimizing degradation and reducing unwanted biological effects. These improvements are expanding the feasibility of RNA therapeutics across a broader range of diseases and encouraging greater investment in the development of next-generation treatment platforms with enhanced clinical performance.

Rising incidence of infectious diseases increasing demand for RNA-based treatments

The increasing prevalence of infectious diseases will propel the RNA therapeutics market growth as healthcare systems prioritize rapid therapeutic development for emerging and recurring pathogens. RNA-based technologies provide flexible platforms that enable researchers to respond efficiently to evolving disease threats through adaptable treatment strategies. This capability is encouraging pharmaceutical developers to strengthen research programs focused on innovative RNA therapeutics capable of addressing infectious diseases with improved precision and accelerated development pathways.

Expanding precision medicine initiatives accelerating RNA therapeutic development pipelines

The growing adoption of precision medicine is strengthening the RNA therapeutics market by supporting therapies designed around individual genetic and molecular characteristics. RNA-based treatments are increasingly being incorporated into personalized healthcare strategies because they can selectively target disease-related biological pathways while complementing advances in genomic analysis and molecular diagnostics. Collaboration between biotechnology companies, research institutions, and healthcare providers is also accelerating the expansion of RNA therapeutic pipelines focused on highly targeted treatment approaches for diverse medical conditions.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Advancements in RNA delivery technologies improving therapeutic effectiveness and safety	2%	High	North America, Europe	High	Mid Term
Rising incidence of infectious diseases increasing demand for RNA-based treatments	1.8%	High	North America, Asia Pacific	High	Near Term
Expanding precision medicine initiatives accelerating RNA therapeutic development pipelines	1.5%	High	North America, Europe	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest share of 38.88% in the RNA therapeutics market in 2026, underpinned by strong biotechnology research capabilities, advanced healthcare infrastructure, and significant activity in novel therapeutic development. RNA-based approaches are gaining attention for their potential to address a broad range of diseases through targeted biological mechanisms, supporting continued research and development across the region. Established clinical research capabilities and investment in advanced drug development technologies are facilitating progress from early-stage discovery toward therapeutic applications. Increasing interest in precision medicine and innovative treatment modalities is also strengthening the regional ecosystem for RNA-based therapies.

Asia Pacific is anticipated to experience the fastest growth, supported by expanding biotechnology capabilities, rising healthcare investment, and increasing research activity focused on advanced therapeutics. Improvements in clinical research infrastructure and the development of domestic pharmaceutical and biotechnology ecosystems are creating favorable conditions for RNA therapeutic development. Growing demand for innovative treatments and greater emphasis on addressing complex and chronic diseases are further encouraging investment in emerging therapeutic platforms. In addition, efforts to strengthen local biopharmaceutical manufacturing and research capabilities are expected to expand the adoption and development of RNA-based therapeutic technologies across the region.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Product Segment Analysis: Vaccines (Largest & Fastest-Growing Segment)

The RNA therapeutics market was led by the vaccines segment, which accounted for 68.83% in 2026 while also emerging as the fastest-growing product category. The segment continues to benefit from the growing adoption of RNA-based vaccine technologies due to their rapid development timelines, high adaptability, and ability to address emerging infectious threats. Continuous advancements in RNA delivery platforms, manufacturing capabilities, and therapeutic research have strengthened confidence in RNA vaccines for both infectious disease prevention and broader clinical applications. Ongoing investments in next-generation vaccine development and expanding research pipelines are expected to further reinforce the segment's dominant position.

Indication Segment Analysis: Infectious Diseases (Largest & Fastest-Growing Segment)

The RNA therapeutics market was dominated by the infectious diseases indication segment, which secured 59.9% in 2026 while also recording the fastest growth. Increasing global efforts to prevent and manage infectious diseases have accelerated the adoption of RNA-based therapeutic approaches capable of delivering rapid and targeted immune responses. The expanding focus on pandemic preparedness, continuous innovation in RNA technologies, and growing investment in infectious disease research continue to strengthen demand within this indication. Broadening clinical applications and sustained research activity are expected to support the segment's continued leadership.

Type Segment Analysis: mRNA Therapeutics (Largest Segment) vs RNA Interference (RNAi) Therapeutics (Fastest-Growing Segment)

Holding the largest share of the RNA therapeutics market, the mRNA therapeutics segment captured 62.98% in 2026. The widespread adoption of messenger RNA technologies has been driven by their ability to direct targeted protein production while offering flexibility for the development of vaccines and therapeutic treatments across multiple disease areas. Continuous advancements in delivery systems and manufacturing processes have further expanded the commercial and clinical potential of mRNA-based therapeutics.

The RNA interference (RNAi) therapeutics segment is expected to witness the fastest growth as increasing research efforts focus on therapies capable of selectively silencing disease-causing genes. RNAi technology offers a highly targeted treatment approach for a broad range of genetic and chronic disorders, encouraging greater investment in clinical development. Improvements in delivery technologies and growing interest in precision medicine are expected to accelerate the adoption of RNAi therapeutics over the coming years.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Vaccines, Drugs
Type	mRNA therapeutics, Antisense oligonucleotide (ASO) therapeutics, siRNA (small interfering RNA) therapeutics, RNA interference (RNAi) therapeutics, Other types
Indication	Infectious diseases, Hereditary/genetic diseases, Autoimmune disorders, Other indications
End-use	Hospitals, Academic & research institutes, Other end-users

Competitive Landscape and Market Positioning

Key companies in the RNA therapeutics market:

1. Moderna, Inc. (United States)
2. BioNTech SE (Germany)
3. Alnylam Pharmaceuticals, Inc. (United States)
4. Ionis Pharmaceuticals, Inc. (United States)
5. Pfizer, Inc. (United States)
6. Novartis AG (Switzerland)
7. Sanofi S.A. (France)
8. Sarepta Therapeutics, Inc. (United States)
9. Arrowhead Pharmaceuticals, Inc. (United States)
10. Regeneron Pharmaceuticals, Inc. (United States)

Scientific progress is steadily redirecting competitive focus from demonstrating therapeutic potential to building platforms that improve delivery efficiency, molecular stability, and manufacturing reproducibility across multiple therapeutic applications. Organizations are investing heavily in technologies that enable broader clinical applicability while addressing formulation and targeted delivery challenges that have historically limited wider adoption. As development programs become more sophisticated, competition increasingly favors participants that can integrate scalable production processes with strong regulatory readiness, allowing promising therapeutic candidates to advance more efficiently through increasingly demanding development pathways.

Industry Development/News

Company Name	Date	Key Development
Macquarie University	Apr-26	Macquarie University opened Australia's first 4,500-square-meter RNA manufacturing facility. Equipped with GMP-compliant cleanrooms capable of producing mRNA, synthetic RNA, and lipid nanoparticle formulations, this infrastructure investment significantly bolsters regional domestic manufacturing capacity for RNA therapeutics and reduces reliance on international supply chains for critical research and clinical-grade materials.
Vivatides Therapeutics	Apr-26	Vivatides Therapeutics raised US$54 million in an oversubscribed Series A financing round. The capital will be deployed to expand its platform for extrahepatic RNA-targeting therapeutics and to accelerate the progression of its pipeline into new, underserved disease areas, reflecting continued investor interest in targeted RNA delivery technologies.
Atrium Therapeutics	Feb-26	Atrium Therapeutics launched as an independent biotechnology firm with US$270 million in funding following the Novartis–Avidity transaction. The company will focus on the development of specialized RNA therapeutics targeting rare genetic cardiomyopathies, signaling a new entrant into the high-value rare disease segment of the RNA therapeutics market.
Acuitas Therapeutics	Jan-26	Acuitas Therapeutics acquired a majority stake in RNA Technologies & Therapeutics to enhance its internal manufacturing capabilities. The move is strategically aimed at securing high-quality, scalable production of RNA constructs, which are essential components for developing and commercializing advanced gene and RNA-based therapies.
Kolon Life Science	Nov-25	Kolon Life Science expanded its pharmaceutical materials portfolio to include phosphoramidite production. By domesticating the supply of this critical raw material, the company aims to strengthen the supply chain resilience and manufacturing stability for RNA therapeutics developers, mitigating risks associated with external sourcing of oligonucleotide synthesis reagents.
Novartis	Oct-25	Novartis agreed to acquire Avidity Biosciences for approximately US$12 billion, a strategic transaction that significantly expands the company's RNA therapeutics portfolio and integrates advanced RNA-targeted drug development programs into its existing research and commercial framework.
Eli Lilly and Company	May-25	Eli Lilly and Company entered a strategic collaboration with Rznomics valued at up to US$1.3 billion to develop novel RNA-based therapies for hearing loss. This partnership underscores the company’s commitment to expanding its internal RNA medicine pipeline through targeted external innovation and therapeutic co-development.
Eli Lilly and Company	Apr-25	Eli Lilly and Company formed a research collaboration with Creyon Bio worth up to US$1 billion to develop AI-enabled oligonucleotide therapeutics. This initiative is designed to strengthen the company’s RNA therapeutics discovery capabilities by leveraging advanced machine learning to accelerate the design and development of precision medicines.
EnPlusOne Biosciences	Feb-25	EnPlusOne Biosciences raised approximately US$10 million to scale its enzymatic RNA synthesis platform. This investment is directed toward transitioning from laboratory-scale research to larger-scale production, addressing current industry bottlenecks in the cost-effective and efficient manufacturing of RNA for broad therapeutic applications.
etherna	Jan-25	etherna partnered with Dropshot in a collaboration valued at up to US$950 million, combining mRNA and lipid nanoparticle (LNP) technologies. The agreement aims to accelerate the development of specialized RNA medicines specifically targeting cardiac and renal diseases, expanding the reach of current mRNA delivery platforms into these critical therapeutic areas.